KYNTRA BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
KYNB$3.90+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements and Supplementary Data
| Page | |
|---|---|
| Kyntra Bio, Inc. | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 69 |
| Financial Statements: | |
| Consolidated Balance Sheets | 71 |
| Consolidated Statements of Operations | 72 |
| Consolidated Statements of Comprehensive Income (Loss) | 73 |
| Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders’ Deficit | 74 |
| Consolidated Statements of Cash Flows | 75 |
| Notes to Consolidated Financial Statements | 76 |
| Financial Statement Schedule: | |
| II. Valuation and Qualifying Accounts for each of the two years ended December 31, 2025 | 111 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.